Table 3 Comparison of clinical signs and outcomes of 190 patients with toxin EIA-negative stool samples or toxin EIA-positive for Clostridiodes difficile

Body temperature > 38.0 °C

85 (44.7)

34 (41.0)

51 (47.7)

0.357

Shock

17 (9.2)

8 (10.1)

9 (8.6)

0.718

Ileus

9 (4.9)

3 (3.8)

6 (5.8)

0.734

Laboratory finding

White blood cell count > 15,000 /µL

44 (24.9)

9 (11.0)

35 (35.4)

< 0.001

Acute kidney injury

12 (6.9)

6 (7.9)

6 (6.2)

0.661

Albumin level, g/dL, mean ± SD

3.2 (2.7–3.8)

3.4 (2.9–4.0)

3.1 (2.7–3.7)

0.057

C-reactive protein, mmol/L, median

(IQR)

48.5 (13.2–95.4)

38.6 (7.9–85.5)

57.5

(19.7–106.5)

0.058

*CDI Treatments

125 (65.8)

29 (34.9)

96 (89.7)

< 0.001

Initial metronidazole

96 (50.5)

24 (28.9)

72 (67.3)

Initial vancomycin

22 (11.6)

3 (3.6)

19 (17.8)

Concomitant use of antibiotics during anti-CDI treatment

97 (51.1)

45 (54.2)

52 (48.6)

0.442

30 d mortality

15 (8.0)

7 (8.5)

8 (7.6)

0.819

30 d mortality among CDI treatment (n = 125)

10 (8.0)

3 (10.3)

7 (7.3)

0.696

CDI development within 60 d

13 (6.3)

4 (4.8)

9 (8.4)

0.331

CDI development within 60 d among CDI treatment (n = 125)

10 (8.0)

1 (3.4)

9 (9.4)

0.451